Extended Data Fig. 6: Immune cells of combination anti-IL-35- plus cGAMP-treated tumours are examined.
From: STING-induced regulatory B cells compromise NK function in cancer immunity
All samples analyzed were obtained from KPC4662 tumour-bearing mice that were injected with cGAMP or PBS control in combination with anti-IL-10, anti-IL-35 or control IgG as depicted in Fig. 4a. a, Frequency (left) and number (right) of tumoral IL-35 producing CD19+ B cells in Fig. 4b. b, Number of tumoral CD45+NK1.1+ cells (left) and NK1.1+ cells expressing GzmB (right) as noted in Fig. 4b. c, Number of tumoral CD45+CD8+ cells (left) and CD8+ T cells expressing TNF (right) as noted in Fig. 4b. d, Frequency (left) and number (right) of tumoral CD8+ T cells expressing GzmB from mice as in Fig. 4b. e, Frequency (left) and number (right) of tumoral CD8+ T cells expressing IFNγ from mice as in Fig. 4b. f, Frequency of tumoral CD45+CD4+CD25- T effector cells from mice as in Fig. 4b. g, Frequency of tumoral CD4+ T cells expressing TNF (left) or IFNγ (right) from mice as in Fig. 4b. h, Frequency of tumoral CD4+Foxp3+ Treg cells from mice as in Fig. 4b. A combination of three experiments (Extended Data Fig. 6a–h) are shown. Mean ± s.e.m. is shown. Unpaired two-tailed Student’s t tests were performed for statistical analysis. P values indicated; ns, not significant.
